×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

CLL

Edward McClain
As Ed completes his final chemo cycle, he loses a friend.
Laura Panjwani
Having multiple options for frontline treatment of CLL may be better than deciding on one standard, an expert says.
Gina Columbus
The treatment landscape for chronic lymphocytic leukemia (CLL) is going to drastically change over the next decade or so, says Jose Leis, M.D.
Novel therapeutic agents have been developed for chronic lymphocytic leukemia (CLL), but their advantage over traditional treatments for this type of cancer have yet to be proved.
Jason M. Broderick
There are now more personalized treatment options for patients with CLL. 
Silas Inman
Arzerra was approved in combination with fludarabine and cyclophosphamide to treat patients with CLL. 
Silas Inman
As new therapies get approved and continue to be investigated, treatment for CLL is rapidly evolving. 
Jason M. Broderick
The FDA expanded the label for Imbruvica for some patients with CLL, as the drug continues to show improved survival benefits. 
Jason M. Broderick
The FDA approved Venclexta for patients with CLL who have a 17p deletion and failed at least one prior therapy.
Andrew J. Roth
The treatment landscape of chronic lymphocytic leukemia is rapidly evolving, according to Jeffrey Jones, an assistant professor at The Ohio State University Comprehensive Cancer Center.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other